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Case 1: Serous tubal cancer detected on PAP
smear
A 60 year old woman with a history of breast cancer
was referred after malignant cells were found on PAP
smear. Abdominal exam, cervical visualisation, transva-
ginal ultrasound and CT of the abdomen and pelvis
were all normal. Endocervical and endometrial curet-
tings demonstrated serous carcinoma cells consistent
with tubal / ovarian origin. CA125 was slightly elevated
at 53 (Upper Limit of Normal 35).
At laparatomy uterus, fallopian tubes and ovaries
appeared normal. She had a hysterectomy, bilateral sal-
pingo-oophorectomy, omentectomy, peritoneal biopsies
and washings. There was no macroscopic evidence of
cancer, but microscopic examination confirmed serous
cancer in the fimbrial end of the left fallopian tube(A)
with scattered malignant cells in the lumen of both fal-
lopian tubes(B), the omentum(C) and surface of the
ovaries(D), surface of uterus and paracolic gutter. Wash-
ings were positive.
Family history was unremarkable. BRCA mutation
screening revealed a BRCA1 mutation. Despite intraperi-
toneal cisplatin and paclitaxel she relapsed and died 4
years later.
Case 2: Positive washing after RRSO in a BRCA 1
mutation carrier
A 40 year old woman had been diagnosed and treated
for breast cancer at age 28. Mutation testing revealed a
BRCA 1 mutation. She elected to have risk reducing sal-
pingo-oophorectomy and hysterectomy at age 40. The
fibria, fallopian tubes and ovaries were examined at
3mm intervals and immunohistochemistry was per-
formed. The right fallopian tube was found to contain
serous tubal intraepithelial carcinoma (STIC) with dif-
fuse p53 staining (E) and Ki-67 seen in 50% of lesional
nuclei (F). Washing were positive for adenocarcinoma
and were similar in appearance to the serous tubal
intraepithelial carcinoma. The left fallopian tube was
found to have a precursor lesion with a p53 signature.
After discussion with her treating oncologist, and
review of the case within the multidisciplinary tumour
board, she elected to undergo adjuvant chemotherapy
for ovarian cancer.
Case 3: Right adnexal mass in residual right
fallopian tube following bilateral oophorectomy
A 60 year woman presented with a right sided pelvic
mass. In 2001 at age 48, she had been diagnosed with
breast cancer. She underwent BRCA 1 or 2 Jewish foun-
der mutation testing which revealed a BRCA1 mutation.
She subsequently had risk reducing bilateral
oophorectomy.
At laparatomy, the pelvic mass was a right adnexal
mass which was a poorly differentiated serous carci-
noma involving the right fallopian tube.
Discussion
Knowledge of origin and evolution of ovarian cancer in
BRCA mutation carriers has lead to changes in proto-
cols of risk reducing surgery is performed and how spe-
cimens from risk reducing surgery are handled. A more
intensive sectioning and staining as well as examination
of peritoneal washing is now standard in most labs.
These cases illustrate the tubal origin of BRCA-related
serous cancers and the propensity for very early dissemi-
nation. In addition, pathology from previous gynaecolo-
gical surgery should be reviewed to ensure complete
removal of ovaries and fallopian tubes.
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